The Prescription That Changed Indian Healthcare: The Real Story of PharmEasy

It was not a grand research report that sparked PharmEasy. It was something far simpler — and far more human.

Dr. Dhaval Shah, a trained medical doctor who had gone on to build a career as a management consultant at McKinsey & Company, kept witnessing a problem that no spreadsheet could fully capture. Elderly patients. Chronic illness. The relentless, exhausting cycle of visiting a pharmacy every few days — often in pain, often alone — to pick up medicines that were sometimes out of stock, sometimes mis-dispensed, and almost never delivered.

India had pharmacies on every street corner. And yet, for millions of people, getting the right medicine reliably was still a struggle. The problem wasn't supply. It was access, organisation, and trust.

Dr. Shah took that problem to his friend Dharmil Sheth — an electronics engineer with an MBA and an entrepreneurial mind that had already tried and built things before. The two men came from the same world: childhood friends from Ghatkopar in Mumbai, along with Harsh Parekh, Siddharth Shah, and Hardik Dedhia — five friends who had known each other since their earliest years. They had already tried their hands at building businesses together, including an online pharmacy called Dialhealth.com as early as 2012, and a distribution business called Ascent Health that followed.

By 2014 and 2015, the friends were ready to try again — this time with the experience, the supply chain knowledge, and the clarity they had lacked the first time around.

Starting Small, Starting Smart

PharmEasy launched in 2015 in Mumbai. The initial funding came from their own families — a gesture of faith that set the tone for everything that followed.

The idea was elegantly simple. A patient uploads their prescription on the PharmEasy app or website. PharmEasy coordinates with a nearby local pharmacy to fulfil the order and delivers the medicines to the patient's doorstep. No queues. No stock uncertainty. No physical strain for someone already unwell.

What made the model genuinely different was what PharmEasy chose not to do. Rather than building massive warehouses and stocking medicines directly, PharmEasy positioned itself as a technology layer that empowered existing neighbourhood pharmacies. It was a pharmacy aggregator — connecting customers with local chemists, giving those chemists a digital presence and a wider customer base, while offering patients the convenience they needed.

As Dharmil Sheth described it in interviews: "We didn't aim to replace pharmacists — we empowered them with reach and tech."

The initial seed funding from their parents was soon followed by Series A funding in 2016, which allowed the company to expand beyond Mumbai and begin its journey across India.

The Five Friends Build a Rocket

Growth came fast. By 2017, with Series B funding in place, PharmEasy's services had reached over 700 cities. The platform was gaining the trust of patients managing chronic conditions — diabetes, hypertension, thyroid disorders — who needed a reliable, repeat supply of medicines and found in PharmEasy exactly that.

The founding team operated with a clarity of roles built over years of friendship. Siddharth Shah, who had conceptualised the original Dialhealth idea during his MBA at IIM Ahmedabad, led the business with strategic vision. Dharmil Sheth managed customer experience, operations, and marketing. Dr. Dhaval Shah — with his MBBS and McKinsey background — brought clinical and strategic depth. Harsh Parekh and Hardik Dedhia rounded out the founding team that had now been building together, in various forms, for nearly a decade.

PharmEasy became the first Indian e-pharmacy to enter the unicorn club — achieving a valuation of $1.5 billion after raising a $323 million funding round from investors including Prosus Ventures and TPG Growth. The milestone was significant not just for the company but for the entire digital health sector in India, which now had proof that the category could attract institutional capital at scale.

Building an Ecosystem, One Acquisition at a Time

Flush with investor confidence and a growing user base, PharmEasy set its sights on becoming more than a medicine delivery platform. The vision was a complete, integrated healthcare ecosystem — medicines, diagnostics, and telehealth, all accessible through a single platform.

The strategy was pursued through acquisitions.

In May 2021, PharmEasy acquired Medlife, a rival e-pharmacy, in what became the largest consolidation deal in India's online pharmacy sector. The merger combined two significant platforms and gave PharmEasy an estimated 60% share of the Indian e-pharmacy market.

Then came the move that made history.

In June 2021, API Holdings — the parent entity of PharmEasy, formed in 2020 by consolidating all group companies — acquired a 66.1% stake in Thyrocare Technologies for ₹4,546 crore at ₹1,300 per share. Thyrocare, founded in 1996 by A. Velumani, was one of India's most recognised and profitable diagnostics chains, with over 3,300 collection centres in more than 2,000 cities. This made PharmEasy the first Indian unicorn to acquire a publicly listed company — a landmark moment in the country's startup history.

The intent was clear: a patient who booked a diagnostic test through PharmEasy, ordered medicines, and consulted a doctor — all within one app — would never need to look elsewhere for healthcare.

The Weight of Ambition

By February 2022, PharmEasy was valued at $5.4 billion. It filed papers for an IPO of ₹6,250 crore in November 2021, with roadshows underway and investor interest reportedly strong.

Then the ground shifted.

In February 2022, the Russia-Ukraine war disrupted global markets. The IPO was shelved. The funding environment tightened globally. PharmEasy, which had taken on significant debt — including a loan from Goldman Sachs — to fund its acquisitions, found itself navigating a difficult financial landscape at exactly the wrong moment.

In August 2022, PharmEasy formally withdrew its IPO plans. A subsequent rights issue in 2023 was raised at a valuation significantly lower than its peak, making it the first Indian unicorn of that funding cycle to raise a down round.

The company acknowledged the weight of the journey. Founders and team members had invested ₹45 crore of their own money by buying shares from investors when the IPO was called off — a signal of their continued belief in what they were building.

The company reduced its workforce and refocused on its core strengths. Siddharth Shah continued to lead the business with a concentration on operational efficiency and the path to profitability. In January 2025, three co-founders — Dharmil Sheth, Dhaval Shah, and Hardik Dedhia — stepped back from day-to-day executive roles while remaining shareholders and board members, allowing the business to enter a new phase of focused leadership.

What PharmEasy Built — and Why It Matters

Despite the financial turbulence of 2022 and 2023, the infrastructure PharmEasy built is real and substantial.

The platform today reaches nearly 98% of India's pin codes. It connects tens of thousands of brick-and-mortar pharmacies and thousands of doctors across the country. Thyrocare continues to operate as India's diagnostics network with its pan-India collection infrastructure. The company reported a 51% reduction in losses to ₹2,533 crore in FY24, reflecting the ongoing effort to stabilise and rebuild.

The investors who stood behind PharmEasy — Prosus, Temasek, TPG, and B Capital among them — have remained engaged, reflecting a long-term view of the digital health opportunity in India.

A Story Still Being Written

The story of PharmEasy is not a clean, triumphant arc. It is the story of five childhood friends who saw a real problem in Indian healthcare, built something meaningful in response to it, scaled that vision aggressively, encountered the consequences of that aggression, and are now — methodically, honestly — finding their footing again.

What they built is not small. The idea that a patient anywhere in India should be able to get their medicines delivered reliably, book a diagnostic test from their phone, and consult a doctor without leaving their home — that idea was radical in 2015. Today, it is an expectation. PharmEasy helped create that expectation.

The road ahead requires the same clarity that brought the five friends from Ghatkopar to the national stage in the first place. Not speed for its own sake, but purpose with discipline. Not ambition unchecked, but vision grounded in operational truth.

India's healthcare system is still being built. And PharmEasy — tested, recalibrated, and still standing — intends to be part of that building.